Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neuroblastoma × SF 1126 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 1 Neoplasms 1

Interventions

Cyclophosphamide 29 Filgrastim 16 Irinotecan 14 Topotecan 13 Temozolomide 12 Melphalan 11 Granulocyte Colony-Stimulating Factor 11 fludarabine 10 Vincristine 10 Peripheral Blood Stem Cell Transplantation 10 Etoposide 9 Isotretinoin 8 Busulfan 8 dinutuximab 7 3-Iodobenzylguanidine 7 humanized 3F8 anti-GD2 monoclonal antibody 6 fludarabine phosphate 6 Interleukin-2 6 Doxorubicin 6 Carboplatin 6 sargramostim 5 aldesleukin 5 Vorinostat 5 Stem Cell Transplantation 5 Cisplatin 5 etoposide phosphate 4 Zoledronic Acid 4 Ipilimumab 4 ribociclib 3 Specimen Handling 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02337309 2018-08-20

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡